2012 provisional classification criteria for polymyalgia rheumatica: a European League Against Rheumatism/American College of Rheumatology collaborative initiative by Dasgupta, Bhaskar et al.
Criteria
Ann Rheum Dis 2012;71:484–492. doi:10.1136/annrheumdis-2011-200329 484
ABSTRACT
The objective of this study was to develop  EULAR/
ACR classiﬁ  cation criteria for polymyalgia rheumatica 
(PMR). Candidate criteria were evaluated in a 6-month 
prospective cohort study of 125 patients with new 
onset PMR and 169 non-PMR comparison subjects with 
conditions mimicking PMR. A scoring algorithm was 
developed based on morning stiffness >45 minutes 
(2 points), hip pain/limited range of motion (1 point), 
absence of RF and/or ACPA (2 points), and absence 
of peripheral joint pain (1 point). A score ≥4 had 68% 
sensitivity and 78% speciﬁ  city for discriminating all 
comparison subjects from PMR. The speciﬁ  city was 
higher (88%) for discriminating shoulder conditions from 
PMR and lower (65%) for discriminating RA from PMR. 
Adding ultrasound, a score ≥5 had increased sensitivity 
to 66% and speciﬁ  city to 81%. According to these 
provisional classiﬁ  cation criteria, patients ≥50 years 
old presenting with bilateral shoulder pain, not better 
explained by an alternative pathology, can be classiﬁ  ed 
as having PMR in the presence of morning stiffness>45 
minutes, elevated CRP and/or ESR and new hip pain. 
These criteria are not meant for diagnostic purposes.
Polymyalgia rheumatica (PMR) is a common inﬂ  am-
matory rheumatic disease of older individuals and 
a common indication for long-term corticosteroid 
therapy.1–3 PMR is also subject to wide variations 
of clinical practice, due to the considerable uncer-
tainty related to diagnosis, course, and manage-
ment in primary and secondary care.4–7 There is 
no diagnostic laboratory test, inﬂ  ammatory mark-
ers are not speciﬁ  c, and clinicians often turn to the 
corticosteroid response as a ‘test of treatment’ to 
establish the diagnosis.1 2 8
Difﬁ  culties in diagnosing and classifying patients 
with PMR are inherent in its deﬁ  nitions.9 10 The 
proximal pain and stiffness syndrome can occur at 
presentation in many other rheumatological inﬂ  am-
matory illnesses in older people.1 2 7 9 Approximately 
half of patients diagnosed with PMR may have 
distal manifestations such as peripheral arthritis, 
hand swelling with pitting oedema and carpal tun-
nel syndrome.1 2 7 11 Polymyalgic presentation is 
common in late-onset rheumatoid arthritis (RA) and 
spondyloarthritis and is also associated with giant 
cell arteritis in 10–30% of cases.1 2 Heterogeneity 
in the disease course, uncertainty regarding disease 
assessment parameters, and evolution of alternative 
diagnoses on follow-up complicate the manage-
ment of PMR.9 12–15For the above reasons a safe and 
speciﬁ  c approach preferring a relative underdiagno-
sis to an overdiagnosis is needed in PMR.9 11
Uniform responsiveness to low doses of cor-
ticosteroids has been assumed to be a cardinal 
feature of PMR. However, there is little hard evi-
dence to substantiate this assertion. A previous 
report showed that 3 weeks after starting predni-
solone 15 mg a day only 55% showed a complete 
response to therapy.10 This also emphasises that 
clinical trials of novel effective agents are needed 
in PMR.
The lack of standardised classiﬁ  cation  criteria 
has been a major factor hampering the develop-
ment of rational therapeutic approaches12 16 17 
and causing difﬁ   culties in evaluating patients in 
clinical studies. In response to a European League 
Against Rheumatism (EULAR)/American College 
of Rheumatology (ACR) initiative, a criteria devel-
opment work group convened in 2005.
A systematic literature review, a three-phase 
hybrid consensus process and a wider survey were 
undertaken to identify candidate criteria items.18 
The ﬁ  rst stage consisted of a meeting of 27 interna-
tional experts who anonymously rated 68 potential 
criteria identiﬁ  ed through literature review. In the 
second round the experts were provided with the 
results of the ﬁ  rst round and re-rated the criteria 
items. In the third round, the wider acceptance of 
the chosen criteria (>50% support) was evaluated 
using a survey of 111 rheumatologists and 53 non-
rheumatologists in North America and western 
Europe.
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clinical and patient-based outcomes in PMR over a 6-month 
period.26 27
Study population
The study was a prospective cohort study that included a 
cohort of patients with new-onset PMR and a comparison 
cohort of non-PMR patients with various conditions mimick-
ing PMR. Study subjects were recruited from 21 community-
based and academic rheumatology clinics in 10 European 
countries and the USA. Inclusion criteria for PMR patients 
were age 50 years or older, new-onset bilateral shoulder pain 
and no corticosteroid treatment (for any condition) within 
12 weeks before study entry, fulfilling all the inclusion and 
exclusion criteria defined by our previous report and in 
accordance with the judgement of the participating inves-
tigator that the patient had PMR.18 Every effort was made 
to choose patients across the spectrum of disease severity. 
Corticosteroid treatment for PMR patients was initiated 
according to a predefined treatment protocol starting with 
15 mg a day oral prednisone for weeks 1 and 2, 12.5 mg 
a day for weeks 3 and 4, 10 mg a day for weeks 6–11, 10 
mg/7.5 mg every other day for weeks 12–15, 7.5 mg a day for 
weeks 16–25 and tapering according to treatment response 
from week 26 onwards. The gold standard for the pre-steroid 
diagnosis of PMR was established as above at presentation 
and when the diagnosis was maintained without an alterna-
tive diagnosis at week 26 of follow-up.
The non-PMR comparison cohort included conditions repre-
sentative of the types that need to be distinguished from PMR, 
in both primary and secondary care. Inclusion criteria for the 
non-PMR comparison cohort were age 50 years or older, new-
onset bilateral shoulder pain and a diagnosis of either inﬂ  am-
matory or non-inﬂ  ammatory conditions, including new-onset 
RA, connective tissue diseases, various shoulder conditions (eg, 
bilateral rotator cuff syndrome and/or adhesive capsulitis, rota-
tor cuff tear, glenohumeral osteoarthritis), ﬁ  bromyalgia, gen-
eralised osteoarthritis and others. Patients known to have the 
condition for more than 12 weeks before the baseline evalu-
ation (except ﬁ  bromyalgia and chronic pain) were not eligible 
for inclusion. PMR patients with clinical suspicion of giant 
cell arteritis were included as part of the comparison cohort 
because these patients required different corticosteroid doses. 
Patients in the comparison cohort were included on the basis 
of clinician diagnosis and not on formal criteria. No guidelines 
were provided for treatment of the conditions in the compari-
son cohort.
Ethics board approval was obtained at all participating insti-
tutions before initiation of the study, and all participants gave 
written informed consent before enrollment.
Follow-up and data collection
PMR patients were evaluated at baseline, and at 1, 4, 12 and 
26 weeks. At each follow-up visit, clinical evaluation included 
response to corticosteroid therapy and opinion on the emergence 
of alternative diagnoses. Patients not considered as having PMR 
at any time were evaluated and treated according to accepted 
clinical practice. They were excluded from the PMR cohort and 
included in the non-PMR comparison cohort. Patients in the 
comparison cohort were evaluated at baseline and at 26 weeks.
Data were collected using standardised data collection forms 
and questionnaires translated into national languages. Data col-
lection included the candidate inclusion/exclusion criteria items 
for classiﬁ  cation of PMR, physical examination and assessment 
In round three, over 70% of respondents agreed on the impor-
tance of seven core criteria (all achieving 100% support in round 
two). These were aged 50 years or older, symptom duration 2 
weeks or longer, bilateral shoulder and/or pelvic girdle aching, 
duration of morning stiffness more than 45 min, elevated eryth-
rocyte sedimentation rate (ESR), elevated C-reactive protein 
(CRP) and rapid corticosteroid response. More than 70% agreed 
on assessing pain and limitation of shoulder (84%) and/or hip 
(76%) on motion, but agreement was low for peripheral signs 
(eg, carpal tunnel syndrome, tenosynovitis, peripheral arthritis).
The group reached consensus on the need for a prospective 
cohort study to evaluate the disease course from presentation 
in patients included on the basis of proximal pain and stiff-
ness with evaluations over a 6-month period while receiving 
a standardised corticosteroid treatment regimen.7 18–25 The 
group also agreed to assess musculoskeletal ultrasound as part 
of the PMR classiﬁ  cation criteria. In this paper, we present the 
results from this prospective study and propose new classiﬁ  ca-
tion criteria for PMR.
STUDY DESIGN AND METHODS
Consensus decisions about study design
A priori, the work group decided that a speciﬁ  c  approach 
should be adopted for classifying newly presenting patients 
with bilateral shoulder pain as PMR.18 The group agreed on the 
following:
Patients presenting with polymyalgic syndrome should  1. 
have stepwise evaluation on the basis of inclusion and 
exclusion criteria, response to a standardised corticosteroid 
challenge and follow-up conﬁ  rmation. The criteria items 
would be agreed upon clinical features and laboratory 
investigations.
The need to standardise response to corticosteroid therapy in  2. 
PMR. Because the goal of classiﬁ  cation criteria is to identify 
patients for enrollment into clinical trials before any treat-
ment, the response to corticosteroid therapy should be used 
in verifying the classiﬁ  cation of a patient as having PMR, 
although it should not be used as a classiﬁ  cation criterion. 
Because scientiﬁ  c evidence is poor as to what constitutes such 
a response it was agreed (>75% agreement) this response 
would be deﬁ  ned as greater than 75% global response in 
clinical and laboratory parameters within 7 days to corticos-
teroid challenge with oral 15 mg prednisone or prednisolone 
and subsequent resolution of inﬂ  ammatory indices.18
That a prospective study would be needed to evaluate  3. 
the disease course from presentation in patients included 
on the basis of the mandatory ‘core’ criteria of proximal 
pain and stiffness. New-onset bilateral shoulder pain was 
selected as the main eligibility criterion as the percentage 
of PMR presenting with hip pain without shoulder pain 
was very small (<5%), and that as hip girdle pain is due 
to a wide range of conditions it would require the enroll-
ment of an impracticably large number of comparator 
patient groups.18 The study would evaluate at prespeci-
ﬁ  ed intervals symptoms, examination, investigations and 
their evolution with standardised corticosteroid treatment 
in a prospective cohort of patients with new-onset bilat-
eral shoulder pain (comparing the PMR case cohort with 
the comparator cohort of mimicking conditions) over a 
6-month period.
Musculoskeletal ultrasound should be evaluated in a substudy  4. 
as a feasible mode of investigation of possible PMR. A sec-
ondary objective of this substudy would be the evaluation of 
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examined and found to represent a similar domain. This tech-
nique allowed a reduction of the number of variables, as one 
variable from each factor was examined in multivariable logistic 
regression models. In addition, to avoid discarding a relevant 
domain as identiﬁ  ed by expert consensus, a few of the variables 
with factor loading between 0.4 and 0.5 were also considered in 
the multivariable models.
Classiﬁ   cation trees including the variables determined by 
the factor analysis were also considered, but were not found 
to be optimal for distinguishing PMR from comparison sub-
jects.31 32 An integer scoring algorithm was deﬁ  ned based on the 
odds ratios in the ﬁ  nal multivariable logistic regression model. 
Performance characteristics (sensitivity, speciﬁ  city, etc.) of this 
scoring algorithm were assessed. In addition, the utility of ultra-
sound assessments for classifying PMR patients was examined 
using factor analysis and adding potential ultrasound criteria 
to the scoring algorithm. Odds ratios for clinical criteria varied 
somewhat in the scoring algorithm that included ultrasound cri-
teria. Scoring weights based on both models were considered 
and found to perform similarly, so a common set of scoring 
weights was used for the clinical items in both algorithms in 
order to ease comparison and application of the criteria.
Finally, gradient boosting regression tree models, which are 
a machine learning technique, were examined to determine 
whether a better prediction could be achieved using a more 
complex algorithm.33
RESULTS
At baseline, 128 patients were recruited into the PMR cohort 
and 184 patients were recruited into the non-PMR comparison 
cohort. During follow-up, 10 PMR patients were reclassiﬁ  ed as 
not having PMR and moved into the non-PMR cohort. Similarly, 
eight non-PMR comparison cohort patients were reclassiﬁ  ed 
as having PMR and moved into the PMR cohort. In addition, 
seven patients (one PMR and six non-PMR) were excluded due 
to missing information, and two non-PMR subjects with age less 
than 50 years and nine non-PMR subjects with no shoulder pain 
were also excluded. Therefore, the ﬁ  nal analysis was based on 
125 PMR and 169 non-PMR subjects.
The diagnoses of the 169 non-PMR subjects (see supplemen-
tary appendix table S2, available online only) were new-onset 
RA (49, 29%), new-onset other seronegative arthritis (20, 12%), 
new-onset connective tissue diseases or vasculitis (9, 5%), 
shoulder conditions (52, 31%), chronic pain (26, 15%), infection 
(5, 3%), previously undiagnosed malignancy (4, 2%), and two 
each of endocrinopathy and neurological disorders.
The distribution of the candidate classiﬁ  cation criteria for the 
125 PMR patients and 169 non-PMR comparison subjects (all, 
RA only and shoulder condition only) is displayed in table 1. 
Criteria items present in over 80% of the PMR subjects were 
2 weeks or greater duration of symptoms, bilateral shoulder 
pain and elevated CRP and/or ESR. Relevant clinical features 
that best discriminated RA from PMR were peripheral synovitis, 
the presence of RF and/or ACPA and hip pain/limited range of 
motion. Features best discriminating shoulder conditions from 
PMR were hip pain/limited range of motion, morning stiffness 
and elevated CRP and/or ESR.
Development of a scoring algorithm
Table 2 shows the results of univariate logistic regression 
models to distinguish PMR from all comparison subjects, RA 
only and shoulder conditions only. Criteria items related to 
hip involvement (pain, tenderness, limited movement) had 
of corticosteroid response. Criteria items were age 50 years or 
older, symptom duration 2 weeks or more, bilateral shoulder 
and/or pelvic girdle aching, recent weight loss greater than 2 kg, 
duration of morning stiffness more than 45 min, elevated ESR, 
elevated CRP and rapid response of symptoms to corticosteroids 
(>75% global response within 1 week to prednisolone/predni-
sone 15–20 mg a day). Pain was assessed using a horizontal 
100 mm visual analogue scale (VAS) in four separate locations 
(shoulder, pelvic, neck and overall) with zero indicating no pain 
and 100 indicating worst pain. Morning stiffness (in the past 
24 h) was assessed in minutes; functional status and quality of 
life were assessed by the modiﬁ  ed health assessment question-
naire (MHAQ) and short form 36. A 100-mm VAS was also used 
for recording global wellbeing measures (patient and physician 
global) and fatigue. Physical examination included the presence 
or absence of tenderness, pain on movement and limitation of 
the shoulders and hips. Aspects of corticosteroid therapy includ-
ing dose, therapeutic response and change in dose and therapy 
discontinuation were documented.
Data regarding laboratory measures (including ESR, CRP, 
rheumatoid factor (RF) and anticitrullinated protein antibody 
(ACPA)) were obtained from clinically ordered tests performed 
at each study centre. As the laboratory assays used at each centre 
varied, test results were classiﬁ  ed as normal/abnormal using the 
reference ranges from each centre (see supplementary appendix 
table S1, available online only). Both PMR and non-PMR sub-
jects underwent ultrasound evaluation of shoulders and hips at 
baseline and at 26 weeks. Evaluations were made according to 
EULAR guidelines28 to assess for features previously reported 
to be associated with PMR, including bicipital tenosynovitis, 
subacromial and subdeltoid bursitis, trochanteric bursitis and 
glenohumeral and hip effusion. A rheumatologist or radiologist 
experienced in musculoskeletal ultrasound performed the ultra-
sound examination using linear probes with the frequency range 
6–10 MHz for shoulders and linear or curved array probes with 
the frequency range 5–8 MHz for hips.
Statistical analysis
Descriptive statistics (means, percentages, etc.) were used to 
summarise the candidate criteria data. Demographics (age and 
gender) and candidate criteria were compared between PMR 
and comparison subjects using χ2 and rank sum tests. Several 
statistical approaches were considered in order to develop a 
scoring algorithm for PMR and to assess the proposed classiﬁ  ca-
tion criteria in patients judged by expert clinician investigators 
to have PMR 26 weeks after enrolment.29
First, logistic regression models to distinguish PMR patients 
from all comparison subjects and each subset of comparison sub-
jects were examined. The c-statistic, a measure of concordance 
analogous to the area under the receiver operating characteristic 
curve, was used to assess the ability of each individual crite-
rion to distinguish between PMR and comparison subjects. The 
c-statistic ranges from 0.5 to 1, with 0.5 indicating a criterion 
that provides no information. The sensitivity, speciﬁ  city and the 
positive and negative likelihood ratios were also examined.
Second, exploratory factor analysis was used to examine the 
interdependencies between the candidate criteria.30 Maximum 
likelihood factor analysis with varimax rotation was used. 
Maximum likelihood tests were used to examine goodness of ﬁ  t 
(eg, to determine the number of factors). This method is thought 
to be superior to the eigenvalue greater than 1 or Catell’s scree 
plot method for selecting the number of factors.30 For each 
factor, variables with factor loadings greater than 0.5 were 
04_annrheumdis-2011-200329.indd   486 04_annrheumdis-2011-200329.indd   486 3/1/2012   12:39:18 PM 3/1/2012   12:39:18 PMCriteria
Ann Rheum Dis 2012;71:484–492. doi:10.1136/annrheumdis-2011-200329 487
or ESR would be included as a required criterion in the scor-
ing algorithm for PMR. Similarly, as all subjects in the study 
were required to have shoulder pain, this was also included as 
a required criterion for PMR.
Factor analysis revealed that four factors were sufﬁ  cient to 
represent all the criteria (see supplementary appendix table S3, 
available online only). These four factors were: hip pain/tender-
ness, peripheral synovitis or other joint pain, morning stiffness 
and shoulder tenderness. Note that duration of symptoms, neck 
aching, carpal tunnel syndrome, weight loss, presence of RF/
ACPA and MHAQ, did not play a prominent role in any of the 
factors.
signiﬁ   cant ability to discriminate PMR from all comparison 
subjects, RA and shoulder conditions based on the c-statistic. 
Early morning stiffness, MHAQ, weight loss and raised labo-
ratory markers of inﬂ  ammation distinguished PMR from com-
parison subjects, particularly those with shoulder conditions. 
The presence of ACPA and/or RF, peripheral synovitis and joint 
pains had signiﬁ  cant ability (with high c-statistic) to distinguish 
PMR from RA. In addition, the odds ratios for abnormal CRP 
and/or ESR were particularly high. This resulted because only 
ﬁ  ve PMR patients did not have abnormal CRP and/or ESR, per-
haps reﬂ  ecting that the diagnosis of PMR is less certain in the 
presence of normal CRP and ESR. Therefore, abnormal CRP 
Table 1  Distribution of candidate criteria for 125 PMR patients and 169 comparison subjects*
  PMR (N=125)
Comparison 
subjects (N=169) p Value RA (N=49) p Value
Shoulder 
conditions† (N=52) p Value
Age, years, mean±SD    71.5±8.4   67.0±9.6 <0.001 68.6±10.0 0.06 67.0±10.6 0.017
Sex (female) 72 (58) 112 (66) 0.13 28 (57) 0.96 35 (67) 0.23
Duration of symptoms ≥2 weeks 121 (97) 163 (96) 0.87 47 (96) 0.77 51 (98) 0.64
Duration of symptoms, weeks, mean±SD 10.0±7.2 14.4±19.1 0.17 13.8±16.1 0.62 12.9±11.8 0.21
Bilateral shoulder aching 124 (99) 162 (96) 0.08 46 (94) 0.035 50 (96) 0.15
Bilateral pelvic girdle (hip) aching 91 (73) 90 (54) 0.001 28 (57) 0.046 21 (40) <0.001
Neck aching 71 (57) 92 (54) 0.69 29 (59) 0.78 27 (52) 0.55
Morning stiffness duration >45 min‡  92 (77) 68 (43) <0.001 33 (69) 0.25 10 (20) <0.001
Morning stiffness, min, median (IQR) 120 (60, 240) 30 (5, 120) <0.001 60 (30, 180) 0.11 10 (0,30) <0.001
Weight loss of >2 kg 45 (36) 40 (24) 0.021 16 (33) 0.68 4 (8) <0.001
Shoulder pain or limited range of motion 121 (97) 158 (93) 0.20 47 (96) 0.77 49 (94) 0.42
Hip pain or limited range of motion 71 (57) 59 (35) <0.001 15 (31) 0.002 12 (23) <0.001
Shoulder tenderness 96 (77) 126 (75) 0.66 40 (82) 0.49 34 (65) 0.12
Hip tenderness 59 (47) 47 (28) 0.001 12 (24) 0.006 9 (17) <0.001
Carpal tunnel syndrome 19 (15) 27 (16) 0.90 11 (22) 0.28 8 (15) 0.99
Peripheral synovitis (distal swelling, 
tenosynovitis or arthritis)‡
48 (39) 78 (46) 0.20 41 (84) <0.001 11 (21) 0.024
Other joint pain‡ 63 (51) 109 (66) 0.011 40 (85) <0.001 29 (57) 0.50
Abnormal CRP and/or ESR‡ 116 (96) 99 (63) <0.001 41 (85) 0.017 18 (41) <0.001
Presence of RF and/or ACPA‡ 11 (10) 37 (25) 0.004 19 (41) <0.001 5 (12) 0.79
Abnormal serum protein electrophoresis‡ 43 (52) 32 (35) 0.027 9 (36) 0.17 9 (35) 0.13
MHAQ, mean±SD  1.2±0.6   0.8±0.6 <0.001  1.1±0.7 0.32  0.5±0.6 <0.001
*Values are number (percentage) unless speciﬁ  ed. Percentages for laboratory results are the number of abnormal tests results divided by the number of patients tested.
ACPA, anticitrullinated protein antibody; CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; MHAQ, modiﬁ  ed health assessment questionnaire; PMR, polymyalgia rheumatica; 
RF, rheumatoid factor.
†Bilateral rotator cuff syndrome and/or adhesive capsulitis, rotator cuff tear, glenohumeral osteoarthritis.
‡Data not available on all subject.
Table 2  Univariate logistic regression models to distinguish subjects with PMR from comparison subjects
PMR vs all 
comparison subjects PMR vs RA
PMR vs shoulder 
conditions*
Variable
Odds ratio 
(95% CI) c
Odds ratio 
(95% CI) c
Odds ratio 
(95% CI) c
Duration of symptoms ≥2 weeks 1.1 (0.3 to 4.0) 0.50 1.3 (0.2 to 7.3) 0.50 0.6 (0.1 to 5.4) 0.51
Shoulder pain or limited range of motion 2.1 (0.7 to 6.8) 0.52 1.3 (0.2 to 7.3) 0.50 1.9 (0.4 to 8.6) 0.51
Shoulder tenderness 1.1 (0.7 to 1.9) 0.51 0.7 (0.3 to 1.7) 0.52 1.8 (0.9 to 3.6) 0.56
Hip pain or limited range of motion 2.5(1.5 to 3.9) 0.61 3.0 (1.5 to 6.0) 0.63 4.4 (2.1 to 9.1) 0.67
Hip tenderness 2.3 (1.4 to 3.8) 0.60 2.8 (1.3 to 5.8) 0.61 4.3 (1.9 to 9.5) 0.65
Neck aching 1.1 (0.7 to 1.8) 0.51 0.9 (0.5 to 1.8) 0.51 1.2 (0.6 to 2.3) 0.52
Morning stiffness duration >45 min  4.5 (2.6 to 7.7) 0.67 1.5 (0.7 to 3.3) 0.54 13.6 (6.0 to 31) 0.79
Weight loss >2 kg 1.8 (1.1 to 3.0) 0.56 1.2 (0.6 to 2.4) 0.52 6.8 (2.3 to 19.9) 0.64
Carpal tunnel syndrome 1.0 (0.5 to 1.8) 0.50 0.6 (0.3 to 1.5) 0.54 – –
Peripheral synovitis (distal swelling, 
tenosynovitis or arthritis)
0.7 (0.5 to 1.2) 0.54 0.1 (0.08 to 0.3) 0.72 2.4 (1.1 to 5.0) 0.59
Other joint pain 0.5 (0.3 to 0.9) 0.57 0.2 (0.1 to 0.4) 0.67 0.8 (0.4 to 1.5) 0.53
Abnormal CRP and/or ESR 13.8 (5.3 to 36) 0.67 4.0 (1.2 to 13) 0.55 33.5 (11 to 98) 0.78
Presence of RF and/or ACPA 0.4 (0.2 to 0.7) 0.57 0.2 (0.07 to 0.4) 0.66 0.9 (0.3 to 2.6) 0.51
Abnormal serum protein electrophoresis 2.0 (1.1 to 3.6) 0.58 1.9 (0.8 to 4.8) 0.58 2.0 (0.8 to 5.1) 0.59
MHAQ (per 1 unit increase) 2.3 (1.6 to 3.4) 0.66 1.3 (0.7 to 2.2) 0.55 6.7 (3.2 to 14) 0.78
ACPA, anticitrullinated protein antibody; c, c-statistic; CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; MHAQ, modiﬁ  ed 
health assessment questionnaire; PMR, polymyalgia rheumatica; RA, rheumatoid arthritis; RF, rheumatoid factor.
*Bilateral rotator cuff syndrome and/or adhesive capsulitis, rotator cuff tear, glenohumeral osteoarthritis.
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included morning stiffness for more than 45 min (two points), hip 
pain/limited range of motion (one point), absence of RF and/or 
ACPA (two points) and the absence of peripheral joint pain (one 
point). The score was evaluated using all PMR subjects (includ-
ing the ﬁ  ve with normal CRP/ESR) and all comparison subjects. 
This was done to account properly for the inﬂ  uence of CRP/
ESR on the performance of the scoring algorithm. A score of 4 
or greater had 68% sensitivity and 78% speciﬁ  city for discrimi-
nating all comparison subjects from PMR. The speciﬁ  city was 
higher (88%) for discriminating shoulder conditions from PMR 
and lower (65%) for discriminating RA from PMR. The c-statis-
tic for the scoring algorithm was 81%. A total of 40 (32%) PMR 
patients and 38 (22%) comparison subjects was incorrectly clas-
siﬁ  ed. The positive predictive value was 69% and the negative 
predictive value was 77%. Supplementary appendix table S4 
(available online only) shows the sensitivity and speciﬁ  city for 
all possible cut points of the scoring algorithm.
Finally, gradient boosting regression tree models, which are 
a model averaging technique, were examined to determine 
whether a better prediction could be achieved using a more 
complex algorithm. The resulting c-statistic from the gradient 
boosting model was 80%, which was quite comparable to the 
results for our scoring algorithm. This indicated that we will not 
be able to make better predictions from these data with another 
modelling approach.
Ultrasound ﬁ  ndings
Ultrasound was performed in 120 PMR subjects, 154 of the com-
parison subjects (including 46 with RA and 47 with shoulder 
conditions) and 21 additional controls (not included in our study 
Next, multivariable logistic regression models were used 
to determine the importance of each criterion when assessed 
simultaneously (table 3). Three models were considered: (1) 
including the four factors identiﬁ  ed in factor analysis; (2) remov-
ing shoulder tenderness and adding presence of RF/ACPA; and 
(3) subsequently adding MHAQ. While the subsequent addi-
tions appeared to be signiﬁ  cant, they also negatively impacted 
the hip pain criteria. The utility of the inclusion of MHAQ was 
questionable, as hip pain was easier to assess than MHAQ in 
a clinical setting. Therefore, the second model, which included 
hip pain, other joint pain, morning stiffness and abnormal RF/
ACPA was deemed the best multivariable model.
Additional analyses were performed using classiﬁ  cation 
trees and assessing combinations of criteria. Classiﬁ  cation trees 
were examined using three sets of potential variables: (1) the 
four identiﬁ  ed factors; (2) adding presence of RF/ACPA; and (3) 
subsequently adding MHAQ. The resulting trees were deemed 
inadequate. For example, the second tree, which was ﬁ  t using the 
same ﬁ  ve variables that were included in our scoring algorithm, 
had a sensitivity of 66% and speciﬁ  city of 66%. This speciﬁ  city 
was lower than the scoring algorithm developed from the logis-
tic models. In addition, this tree only included morning stiffness 
and absence of RF and/or ACPA, so it was inadequate because 
it excluded other domains deemed necessary for content valid-
ity. Content validity requires that the set of criteria identiﬁ  ed is 
comprehensive. This was the case in all three trees. Therefore, 
classiﬁ  cation trees were deemed to have poorer performance 
and content validity than the logistic regression models.
A scoring algorithm was developed (table 4) based on the 
multivariable logistic regression model presented in table 3 and 
Table 3  Multivariable logistic regression models
Model based on factors
Model based on factors without shoulder 
tenderness plus presence of RF/ACPA
Model based on factors plus 
presence of RF/ACPA and MHAQ
Criterion Odds ratio (95% CI) p Value Odds ratio (95% CI) p Value Odds ratio (95% CI) p Value
Hip pain or limited hip range of motion   2.7 (1.5 to 4.8) 0.001   2.1 (1.1 to 4.0) 0.019 1.6 (0.8 to 3.2) 0.16
Other joint pain   0.4 (0.2 to 0.6) <0.001   0.4 (0.2 to 0.7) 0.002 0.3 (0.1 to 0.6) <0.001
Morning stiffness >45 min duration   5.2 (2.9 to 9.4) <0.001   6.2 (3.2 to 11.8) <0.001 4.8 (2.4 to 9.6) <0.001
Shoulder tenderness   0.9 (0.5 to 1.8) 0.80
Presence of RF or ACPA   0.3 (0.1 to 0.8) 0.009 0.3 (0.1 to 0.8) 0.013
MHAQ, per 1 unit increase 2.4 (1.4 to 4.2) 0.002
Likelihood ratio test for additional terms p<0.001 p<0.001
c-Statistic 79% 81% 81%
ACPA, anticitrullinated protein antibody; MHAQ, modiﬁ  ed health assessment questionnaire; RF, rheumatoid factor.
Table 4  Scoring algorithm with and without optional ultrasound criterion—required criteria: age 50 years or greater, bilateral shoulder aching and 
abnormal CRP and/or ESR
  Clinical criteria (without ultrasound)* Criteria including ultrasound†
Criteria Odds ratio (95% CI) Points Odds ratio (95% CI) Points
Morning stiffness duration >45 min  6.2 (3.2 to 11.8) 2 5.0 (2.8 to 9.1) 2
Hip pain or limited range of motion 2.1 (1.1 to 4.0) 1 1.4 (0.8 to 2.6) 1
Absence of RF or ACPA 3.0 (1.3 to 6.8) 2 5.2 (2.1 to 12.6) 2
Absence of other joint pain 2.7 (1.4 to 5.0) 1 2.2 (1.3 to 4.0) 1
Ultrasound criteria
At least one shoulder with subdeltoid bursitis 
and/or biceps tenosynovitis and/or glenohumeral 
synovitis (either posterior or axillary) and at least 
one hip with synovitis and/or trochanteric bursitis
2.6 (1.3 to 5.3) 1§
Both shoulders with subdeltoid bursitis, 
biceps tenosynovitis or glenohumeral synovitis  
  2.1 (1.2 to 3.7) 1¶
ACPA, anticitrullinated protein antibody; CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; RF, rheumatoid factor; CI, conﬁ  dence interval.
*The optimal cut point is 4. A patient with a score of 4 or more is categorised as having polymyalgia rheumatica (PMR).
†The optimal cut point is 5. A patient with a score of 5 or more is categorised as having PMR.
§ P = 0.008. 
¶ P = 0.009.
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but less so in discriminating PMR from RA. Table 4 also shows the 
scoring algorithm including the ultrasound criteria. Supplementary 
appendix table S4 (available online only) shows the sensitivity and 
speciﬁ  city for all possible cut points of the scoring algorithm.
Response to corticosteroids in PMR
Complete corticosteroid response at 4 weeks was seen in 71% 
of patients and the response was sustained in 78% of respond-
ers at 26 weeks. As expected by the plan for tapering of the 
corticosteroids, the median prednisone dose decreased from 15 
mg at baseline to 5 mg at 26 weeks. Response to treatment (per-
centage improvement in global pain VAS at weeks 4 and 26) 
was highly correlated with percentage improvement in other 
VAS measures (correlation >0.5 and p<0.001 at weeks 4 and 26), 
but was not correlated with percentage change in corticosteroid 
dose (p=0.20 at week 4 and p=0.47 at week 26). There was no 
association between the points obtained on either scoring algo-
rithm and the response to corticosteroids at 4 weeks (Spearman 
correlation coefﬁ   cient 0.09; p=0.38 for the scoring algorithm 
including ultrasound) and 26 weeks (data not shown), indicat-
ing that corticosteroid response can not be used as part of PMR 
classiﬁ  cation.
cohorts) who did not have shoulder conditions. Patients with 
PMR were more likely to have abnormal ultrasound ﬁ  ndings in 
the shoulder (particularly subdeltoid bursitis and biceps teno-
synovitis), and somewhat more likely to have abnormal ﬁ  ndings 
in the hips than comparison subjects as a group (table 5). PMR 
could not be distinguished from RA on the basis of ultrasound, 
but could be distinguished from non-RA shoulder conditions 
and subjects without shoulder conditions.
Assessing the utility of ultrasound in classifying PMR
Factor analysis (see supplementary appendix table S5, available 
online only) revealed several strong factors potentially useful for clas-
sifying patients with PMR from the ultrasound data. The inclusion 
of ultrasound ﬁ  ndings in the scoring algorithm resulted in improving 
the c-statistic to 82%. A score of 5 or greater had 66% sensitivity and 
81% speciﬁ  city for discriminating all comparison subjects from PMR. 
The speciﬁ  city was higher (89%) for discriminating shoulder condi-
tions from PMR and lower (70%) for discriminating RA from PMR. 
A total of 41 (34%) PMR patients and 30 (19%) comparison subjects 
was incorrectly classiﬁ  ed. The positive predictive value was 72% and 
the negative predictive value was 75%. Therefore, ultrasound ﬁ  nd-
ings were useful in discriminating PMR from shoulder conditions, 
Table 5  Ultrasound ﬁ  ndings in 120 patients with PMR, 154 comparison subjects (including 46 with RA and 
47 with shoulder conditions) and 21 subjects without shoulder conditions
 
PMR 
(N=120)
Comparison 
subjects (N=154) RA (N=46)
Shoulder 
condition (N=47)
Subjects without 
shoulder conditions 
(N=21)
At least one shoulder with 
subdeltoid bursitis, biceps 
tenosynovitis or glenohumeral 
synovitis
83% 70%** 78% 62%** 19%**
Both shoulders with subdeltoid 
bursitis, biceps tenosynovitis or 
glenohumeral synovitis
59% 43%** 65% 26%**  0%**
At least one shoulder with subdeltoid 
bursitis or biceps tenosynovitis
82% 63%** 72% 53%** 19%**
Both shoulders with subdeltoid 
bursitis or biceps tenosynovitis
57% 35%** 52% 21%**  0%**
At least one hip with synovitis or 
trochanteric bursitis
38% 23%* 30% 18%*  0%**
Both hips with synovitis or 
trochanteric bursitis
19% 8%**  9%  4%*  0%*
At least one shoulder and one hip 
with ﬁ  ndings as above
33% 16%** 17%* 11%**  0%**
Both shoulder and both hips with 
ﬁ  ndings as above
12%  7%  6%  2%*  0%
*p<0.05 compared with PMR.
**p<0.01 compared with PMR.
PMR, polymyalgia rheumatica; RA, rheumatoid arthritis.
Table 6  PMR classiﬁ  cation criteria scoring algorithm—required criteria: age 50 years or older, bilateral 
shoulder aching and abnormal CRP and/or ESR*
  Points without US (0–6) Points with US† (0–8)
Morning stiffness duration >45 min  2 2
Hip pain or limited range of motion 1 1
Absence of RF or ACPA 2 2
Absence of other joint involvement 1 1
At least one shoulder with subdeltoid bursitis and/or biceps tenosynovitis 
and/or glenohumeral synovitis (either posterior or axillary) and at least one 
hip with synovitis and/or trochanteric bursitis
Not applicable 1
Both shoulders with subdeltoid bursitis, biceps tenosynovitis or 
glenohumeral synovitis
Not applicable 1
*A score of 4 or more is categorised as PMR in the algorithm without US and a score of 5 or more is categorised as PMR in the 
algorithm with US.
†Optional ultrasound criteria.
ACPA, anticitrullinated protein antibody; CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; PMR, polymyalgia rheumatica; 
RF, rheumatoid factor; US, ultrasound.
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and 0–8 (with ultrasound). In the absence of competing diagno-
ses, a score of 4 or greater (without ultrasound), or 5 or greater 
(with ultrasound) is indicative of PMR. Patients with a score of 
less than 4 (based on clinical plus laboratory criteria) cannot be 
considered to have PMR. Ultrasound improves the speciﬁ  city of 
PMR diagnosis, and shows particularly good performance in dif-
ferentiating PMR from non-inﬂ  ammatory conditions and thus is 
a recommended investigation for PMR.
Classiﬁ  cation criteria for PMR should be useful for identifying 
patients appropriate for enrollment into clinical trials of novel 
medications for the treatment of PMR, and studying long-term 
outcomes in more homogeneous patient cohorts. Our analyses 
indicate that even typical PMR patients at presentation may vary 
in their response to low-dose corticosteroid therapy, indicating 
that corticosteroid response is not reliable as a classiﬁ  cation fea-
ture for PMR. This is similar to other rheumatic diseases such as 
RA, in which phenotypically similar patients may exhibit differ-
ent responses to disease-modifying antirheumatic drugs.
Strengths and limitations
The strengths of the study relate to harnessing international 
effort to address a disease area subject to wide variation of prac-
tice; to develop agreement on the deﬁ  nition of what may or may 
not be treated as PMR and what needs further evaluation.
Our study methodology satisﬁ  es the ACR guidelines for the 
development of classiﬁ  cation criteria for rheumatic diseases.35 
The consensus-based candidate criteria were generated by 
a multispecialty international group whose views were sup-
ported by the results of a wide trans-Atlantic survey. The work 
group suggested a prospective study designed to separate PMR 
patients from comparison subjects in patients included on a sin-
gle eligibility criterion (new bilateral shoulder pain in subjects 
≥50 years).
This ensured an inception cohort longitudinal observational 
design wherein the PMR cohort could be compared with the 
comparison cohort at similar chronological time points of dis-
ease. All PMR patients were evaluated before treatment with 
corticosteroids, were treated with a standard corticosteroid 
schedule and assessed at predetermined time points. Our study 
is in keeping with the EULAR/ACR goal of developing rheumatic 
disease classiﬁ  cation criteria as opposed to diagnostic criteria. 
We focused on subjects with new-onset/incident disease, and a 
6-month longitudinal follow-up allowed an accurate evaluation 
of the disease course and diagnoses. Previous criteria for PMR 
were developed using cross-sectional comparisons. Only two 
of the previous criteria were developed through an evaluative 
process.20 36 Neither had a deﬁ  nition of the ‘gold standard’ diag-
nosis other than the physician considered the patient to have 
‘unequivocal’ PMR.
Another strength of our proposed classiﬁ  cation criteria is the 
imaging component. Musculoskeletal ultrasound has promise 
due to widespread availability, feasibility and good research evi-
dence.18 The PMR work group standardised the examination of 
shoulders and hips by ultrasound for the purposes of the cur-
rent study.37 Our ﬁ  ndings indicate that ultrasound evaluation of 
hips and shoulders adds signiﬁ  cantly to the evaluation of the 
polymyalgic syndrome. The lack of a ‘gold standard’ and the 
challenge of circularity was addressed through a blinded multi-
rater re-evaluation exercise in selected cases and comparison 
subjects (in supplementary appendix 2, available online only). 
Most of the candidate criteria items performed well. The mis-
classiﬁ  cation of several subjects reﬂ  ects the difﬁ  culty in discrimi-
nating PMR from other inﬂ  ammatory conditions such as RA. 
This uncertainty originates from the pivotal role of (and circular 
We also re-evaluated our risk score model for the scoring algo-
rithm using only the PMR subjects who responded to corticos-
teroids. When the ﬁ  nal risk score model was re-computed using 
only the subset of subjects with PMR who responded to corti-
costeroids (and all of the comparison subjects), the odds ratios 
for each of the criteria remained essentially unchanged. In addi-
tion, the speciﬁ  city was identical and the sensitivity increased 
by an insigniﬁ  cant amount (0.5%).
Blinded re-evaluation of selected PMR patients 
and non-PMR controls
The re-evaluation exercise showed that most candidate criteria 
items performed well in discriminating PMR patients from con-
trols. However, a third of the sample of PMR patients/compari-
son subjects was difﬁ  cult to classify. The high c-statistic levels 
associated with the corticosteroid response and post-treatment 
CRP and ESR suggested that the uncertainty originated from the 
pivotal role of corticosteroids in the investigator assessment, in 
deciding whether a patient does or does not have PMR. It raises 
questions such as whether PMR always responds adequately 
to corticosteroids and whether polymyalgic RF-positive dis-
ease without peripheral synovitis can occur (see supplementary 
appendix 2, available online only, for details).
DISCUSSION
This is the ﬁ   rst international multicentre prospective study 
examining consensus-based candidate classiﬁ  cation criteria for 
PMR proposed by an international work group. Findings indi-
cate that patients 50 years of age or older presenting with new 
bilateral shoulder pain (not better explained by an alternative 
diagnosis) and elevated CRP and/or ESR can be classiﬁ  ed as hav-
ing PMR in the presence of morning stiffness for more than 45 
min, and new hip involvement (pain, tenderness, limited move-
ment). The absence of peripheral synovitis or of positive RA 
serology increases the likelihood of PMR. While recognising 
that RF particularly may be present in patients with PMR, the 
absence of RF serology is useful in distinguishing PMR from RA 
in older patients for classiﬁ  cation purposes.18 34 Ultrasound ﬁ  nd-
ings of bilateral shoulder abnormalities (subacromial bursitis/
bicipital tenosynovitis/glenohumeral effusion) or abnormalities 
in one shoulder and hip (hip effusion, trochanteric bursitis) may 
signiﬁ  cantly improve the speciﬁ  city of the clinical criteria. These 
criteria are not meant for diagnostic purposes and have not been 
tested as diagnostic criteria.
Newer concepts of PMR are revealed by this and other recent 
studies—heterogeneity at presentation and course, lack of uni-
form responsiveness to low-dose steroids and overlap with 
inﬂ  ammatory arthritis. However, we feel that at present these 
classiﬁ  cation criteria provide a basic framework for developing 
clinical trials of novel therapies in PMR.
How should the PMR classiﬁ  cation criteria be applied?
The target population will be patients aged 50 years or older 
presenting with new-onset (<12 weeks) bilateral shoulder pain 
and abnormal acute phase response. The criteria may only be 
applied to those patients in whom the symptoms are not bet-
ter explained by an alternative diagnosis. Mimicking conditions 
include the inﬂ   ammatory and non-inﬂ  ammatory  conditions 
studied as comparators in this report.
Four clinical and laboratory criteria along with optional ultra-
sound criteria (table 4 and table 6) can be applied to eligible 
patients to identify patients with PMR suitable for low-dose cor-
ticosteroid therapy. The scoring scale is 0–6 (without ultrasound) 
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reasoning related to using) the corticosteroid response in decid-
ing whether a patient does or does not have PMR. Although the 
proposed scoring algorithm has high speciﬁ  city for identifying 
PMR patients,, it is nevertheless unable to predict the subse-
quent corticosteroid response, suggesting heterogeneity of dis-
ease course and treatment response. This has also been reported 
previously.10 38
While we were able to scrutinise the basis for PMR diagnosis, 
no formal criteria were required for diagnosis of the comparison 
conditions. This is a limitation of the study. However, the study 
was led in all centres by experienced rheumatologists with major 
clinical and research interest in PMR and related conditions. We 
did not include hip pain without shoulder pain as an eligibility 
criterion for reasons discussed in the ‘Methods’ section. Funding 
constraints limited the follow-up duration to only 6 months. We 
were also limited by lack of funding for the central measure-
ment of laboratory data. Values of ESR, CRP, RF and ACPA were 
based on local laboratory assays. Our study approach reﬂ  ects a 
pragmatic view, which perhaps lends wider applicability to the 
results of the study.
Our classiﬁ  cation algorithm had a c-statistic of 81%, which 
exceeds the threshold of 80% that is conventionally considered 
to be useful in clinical decision-making. However, we suggest 
that the criteria are regarded as provisional at this point awaiting 
validation in a separate cohort.
In conclusion, patients aged 50 years or older presenting 
with bilateral shoulder pain and elevated CRP and/or ESR can 
be classiﬁ  ed as having PMR in the presence of morning stiff-
ness for more than 45 min, and new hip pain in the absence of 
peripheral synovitis or positive RA serology. Using ultrasound, 
a score of 5 or greater had 66% sensitivity and 81% speciﬁ  city 
for discriminating all comparison subjects from PMR. In our 
view, this approach can now be used to test eligibility for tri-
als with newer therapies in PMR. A number of future research 
questions are highlighted, including: (1) Should PMR be con-
sidered as a part of the spectrum of late-onset inﬂ  ammatory 
arthritis? (2) Can polymyalgic disease without peripheral syn-
ovitis occur in RF-positive disease? (3) Can we diagnose PMR 
in patients with normal acute phase response? (4) What is the 
role of the early introduction of disease-modifying antirheu-
matic drugs in PMR?
We have collected and stored blood samples from both 
the case and the comparator groups in the study. We hope to 
develop research proposals using these biospecimens to test 
several candidate biomarkers in PMR. These proposals will 
also examine the acute phase response; whether stratiﬁ  cation 
of the response and differential levels of acute phase reactants 
and cytokines may function as additional classiﬁ  cation criteria 
items.
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